Imatinib Sandoz

Imatinib, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumors in adult patients.

GNH USA supplies Imatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid‑tumor indications. - Chronic myeloid leukemia (CML): reduces disease progression by targeting the BCR‑ABL fusion protein. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth driven by c‑KIT mutations.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea - Diarrhea - Edema - Fatigue - Muscle cramps - Rash

Serious or Rare Side Effects: - Neutropenia - Hepatotoxicity - Cardiac failure - Severe hemorrhage - Pulmonary hypertension - Interstitial lung disease

Before initiating therapy and throughout treatment, several safety considerations are recommended. - Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: check hepatic enzymes periodically. - Evaluate cardiac status: baseline and periodic ECG or echocardiogram may be warranted. - Pregnancy: avoid use unless potential benefit justifies the risk. - Review concomitant CYP3A4 modulators: adjust therapy as needed. - Store at below 25°C: keep in the original pack, protect from moisture.

Imatinib may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Concomitant use with antacids that markedly raise gastric pH: can impair absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly raise concentrations. - Moderate CYP3A4 inducers (e.g., phenobarbital, phenytoin): may modestly lower concentrations. - Warfarin: monitor INR for potential anticoagulation changes. - Live vaccines: assess risk before administration.